

# CERVICAL CANCER

## COMBINED MODALITY THERAPY

### CISPLATIN (WEEKLY) – RADIATION THERAPY – ADJUVANT HYSTERECTOMY

Cisplatin	40 mg/m <sup>2</sup>	IV*	Q Week**
Radiation	1.8 – 2 Gy daily, 5 days per week for a total dose of 45 Gy, followed by local brachytherapy.		

\*Routine pre- and post-hydration required; \*\*Maximum 6 doses. Cap weekly dose at 70 mg.

NOTE: Hysterectomy followed by 3 – 6 weeks after completion of chemo-radiotherapy.

Reference: [Keys HM, et al. \*N Engl J Med\* 1999;340:1154 – 61.](#)

### CISPLATIN – 5-FLUOROURACIL – PELVIC RADIATION

Cisplatin	75 mg/m <sup>2</sup>	IV*	Day 1
5-Fluorouracil	1000 mg/m <sup>2</sup> /day	CIVI	Days 1 – 4
Radiation	1.8 Gy daily, 5 days per week for a total dose of 45 Gy followed by local brachytherapy.		

\*Administer over 4 hours with routine pre- and post-hydration;

Repeat cycle every 21 days for 3 total cycles. The final cycle should be concurrent with brachytherapy placement.

References: [Eifel PJ, et al. \*J Clin Oncol\* 2004;22:872 – 80;](#) [Morris M, et al. \*N Engl J Med\* 1999;15;340:1137 – 43.](#)

## CERVICAL CANCER CHEMOTHERAPY

### CISPLATIN (ADVANCED/UNRESECTABLE)

Cisplatin	50 – 100 mg/m <sup>2</sup>	IV*	Day 1
-----------	----------------------------	-----	-------

\*Adequate pre- and post-hydration should be administered. Administer at a rate of 1 mg/minute.

Repeat cycle every 21 days for up to 4 cycles or 400 mg/m<sup>2</sup> total dose.

Reference: [Bonomi P, et al. \*J Clin Oncol\* 1985;3:1079 - 85.](#)

### CISPLATIN – IFOSFAMIDE (ADVANCED/RECURRENT)

Cisplatin	50 mg/m <sup>2</sup>	IV*	Day 1
Ifosfamide	5000 mg/m <sup>2</sup>	CIVI**	Day 1
Mesna	6000 mg/m <sup>2</sup> /day	CIVI**	Days 1 and 2 <sup>#</sup>

\*Adequate pre- and post-hydration; \*\*Administer as a continuous 24 hour infusion; #Mesna infusion to run for an additional 12 hours following completion of the ifosfamide dose.

Repeat cycle every 21 days for a maximum of 6 cycles.

Reference: [Bloss JD, et al. \*J Clin Oncol\* 2002;20:1832 - 7.](#)

### CISPLATIN – TOPOTECAN

Topotecan	0.75 mg/m <sup>2</sup> /day	IV*	Days 1 – 3
Cisplatin	50 mg/m <sup>2</sup>	IV**	Day 1

\*Administer over 30 minutes; \*\*Adequate pre- and post-hydration should be administered; Administer at a rate of 1 mg/minute.

NOTE: Dose calculations were based on a maximum BSA of 2 m<sup>2</sup>.

DOSE MODIFICATIONS: The cisplatin dose was reduced by 50% for grade 2 renal toxicity and held for the present cycle for grade 3 or 4 renal toxicity on the scheduled day of re-treatment. Topotecan was reduced by 20% for grade 3 and by 40% for grade 4 interval hematological toxicity for the entire course of therapy. Patients were able to receive filgrastim during subsequent cycles of therapy if febrile neutropenia occurred after dose modification for hematological toxicity during the previous cycle of therapy.

Repeat cycle every 21 days to a maximum of 6 cycles.

Reference: [Long HJ, et al. \*J Clin Oncol\* 2005;23:4626 - 33.](#)

### **GEMCITABINE – CISPLATIN**

Cisplatin	30 mg/m <sup>2</sup>	IV*	Days 1 and 8
Gemcitabine	800 mg/m <sup>2**</sup>	IV	Days 1 and 8

\*Routine pre- and post-hydration should be administered; \*\*Gemcitabine increased to 1000 mg/m<sup>2</sup> at cycle 2 in those with less than grade 3 nausea and vomiting, less than grade 2 other non-hematologic toxicity, and less than grade 2 hematologic toxicity during cycle 1.

Repeat cycle every 28 days until intolerance or disease progression.

Reference: [Brewer CA, et al. \*Gynecol Oncol\* 2006;100:385 – 8.](#)

### **PACLITAXEL – CISPLATIN**

Paclitaxel <sup>‡</sup>	135 mg/m <sup>2</sup>	CIVI*	Day 1
-------------------------	-----------------------	-------	-------

*Followed immediately by*

Cisplatin	50 <sup>1</sup> – 75 <sup>2</sup> mg/m <sup>2</sup>	IV**	Day 2
-----------	---	------	-------

‡Routine premedication administered; \*Administer as a continuous 24-hour infusion; \*\*Administer at a rate of 1 mg/minute. Routine pre- and post-hydration required.

Repeat cycle every 21 days to a maximum of 6 cycles.

References: <sup>1</sup>[Moore DH, et al. \*J Clin Oncol\* 2004;22:3113 – 9;](#) <sup>2</sup>[Rose PG, et al. \*J Clin Oncol\* 1999;17:2676 – 80.](#)

### **PACLITAXEL – CISPLATIN**

Paclitaxel <sup>‡</sup>	175 mg/m <sup>2</sup>	IV*	Day 1
-------------------------	-----------------------	-----	-------

*Followed by*

Cisplatin	75 mg/m <sup>2</sup>	IV**	Day 1
-----------	----------------------	------	-------

‡Routine premedication administered; \*Administer over 3 hours; \*\*Administer over 2 hours. Routine pre- and post-hydration required.

Repeat cycle every 21 days for a maximum of 6 cycles.

Reference: [Papadimitriou CA, et al. \*J Clin Oncol\* 1999;17:761 – 6.](#)